COMPASS Pathways plc (CMPS) stock
Close on Nov 11, 2026Market cap $1.29BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.29B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 15.23
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$394.19M
- EPS, diluted
- -$4.60
- Book value per share
- $0.63
- Diluted shares
- 135M
Trading
- Next earnings
- Mar 23, 2027 (estimated, before the open)
- Previous close
- $9.25
- Open
- $9.50
- Day's range
- $9.03 – $9.50
- Volume
- 2,624,257
- Average volume (20 days)
- 3,822,219
- Beta (5 years)
- 1.61
- 52-week range
- $4.88 – $15.87
- RSI (14 days)
- 40.0
- Volatility (1 year)
- 92.9%
- Relative volume
- 0.78×
- WACC
- 12.7%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CMPS | S&P 500 | Difference | CMPS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.5% | -2.4% | −20.1 pts | ||
| 3 months | -30.5% | -1.2% | −29.3 pts | ||
| Year to date | +34.8% | +12.3% | +22.5 pts | ||
| 1 year | +63.2% | +12.4% | +50.7 pts | ||
| 3 years | +76.5% | +78.8% | −2.3 pts | +20.8% | +21.4% |
| 5 years | -73.0% | +75.2% | −148.2 pts | -23.0% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases COMPASS Pathways filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About COMPASS Pathways
Pharmaceutical Preparations
The company is a clinical-stage biotechnology business that develops evidence-based therapeutic options for serious mental health conditions. Its primary product candidate is COMP360, an investigational formulation of pharmaceutical-grade crystalline psilocybin designed to induce rapid and durable treatment responses. The firm focuses on therapeutic indications that include treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa. Its target patient populations consist of individuals living with severe psychiatric disorders who do not experience adequate relief from existing conventional medications and therapies.
Company profile, executives and historyCOMPASS Pathways stock: common questions
What is COMPASS Pathways's stock price?
CMPS closed at $9.30 on Nov 11, 2026, up 0.54% on the day. Over the past 52 weeks it traded between $4.88 and $15.87.
What is COMPASS Pathways's market cap?
COMPASS Pathways was worth $1.29B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CMPS's P/E ratio?
COMPASS Pathways lost money over the twelve months to Jun 30, 2026 (diluted EPS -$4.60), so it has no meaningful P/E ratio.
Does COMPASS Pathways pay a dividend?
No. COMPASS Pathways has not paid a cash dividend over the last twelve months.
When does COMPASS Pathways report earnings next?
COMPASS Pathways is expected to report Q4 FY2026 results on Mar 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CMPS stock performed over the past year?
Including dividends, CMPS returned +63.2% over the past year, against +12.4% for the S&P 500.
Who are COMPASS Pathways's competitors?
Companies most similar to COMPASS Pathways by business, industry and size include PBM, ANRO, VTGN, KTTA, IXHL.
See a number that looks wrong?